Aura Biosciences to Participate in Upcoming Investor Conferences
May 24 2023 - 4:05PM
Business Wire
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced that Elisabet de los Pinos, PhD, Chief Executive Officer,
will participate in the following upcoming investor
conferences:
- TD Cowen 4th Annual Oncology Innovation Summit on Tuesday,
May 30, 2023. Fireside Chat at 10:00 a.m. ET.
- Jefferies Healthcare Conference on Thursday, June 8,
2023. Presentation at 9:00 a.m. ET.
The live webcasts of the fireside chat and presentation will be
available on the “Investors & Media” page under the “Events
& Presentations” section of the Company’s website at
https://ir.aurabiosciences.com/events-and-presentations, where a
replay of the webcast will be archived for 90 days following the
presentation date.
About Aura Biosciences
Aura Biosciences, Inc., is a clinical-stage biotechnology
company developing virus-like drug conjugates (VDCs), a novel class
of therapies, for the treatment of multiple oncology indications.
Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar;
AU-011), consists of a virus-like particle conjugated with an
anti-cancer agent. Bel-sar is designed to selectively target and
destroy cancer cells and activate the immune system with the
potential to create long-lasting anti-tumor immunity. Bel-sar is
currently in development for ocular cancers, and Aura has initiated
activities for the global Phase 3 trial evaluating first-line
treatment of early-stage choroidal melanoma, a vision- and
life-threatening form of eye cancer where standard of care with
radiotherapy leaves patients with severe comorbidities, including
major vision loss. Aura plans to pursue development of bel-sar
across its ocular oncology franchise including for the treatment of
patients with choroidal metastasis. In addition, leveraging Aura’s
technology platform, Aura is developing bel-sar more broadly across
multiple cancers, including in patients with non-muscle invasive
bladder cancer. Aura is headquartered in Boston, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230524005856/en/
Investors and Media: Alex Dasalla Head of Investor
Relations and Corporate Communications
adasalla@aurabiosciences.com
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2023 to Apr 2024